Floatz logo

Carboplatin

Squamous NSCLC

Gruppo Oncologico Italiano di Ricerca ClinicaSmall moleculePhase 3Active
BBB
76/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Squamous NSCLC cohort.

Asset / SponsorPhaseRating
Chir-258
Samsung Medical Center
Phase 2CCC
CV09070101 mRNA vaccine (CVHNLC)
CureVac
Phase 1CC

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →